{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:27:16Z","timestamp":1774312036470,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Next\u2010day residual effects of a nighttime dose of gabapentin 250\u2009mg were evaluated on simulated driving performance in healthy participants in a randomized, placebo\u2010controlled, double\u2010blind, multicenter, four\u2010period crossover study that included diphenhydramine citrate 76\u2009mg and triazolam 0.5\u2009mg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>At treatment visits, participants (<jats:italic>n<\/jats:italic>\u2009=\u200959) were dosed at ~23:30, went to bed immediately, and awakened 6.5\u2009h postdose for evaluation. The primary endpoint was the standard deviation of lateral position for the 100\u2010km driving scenario. Additional measures of driving, sleepiness, and cognition were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Study sensitivity was established with triazolam, which demonstrated significant next\u2010day impairment on all driving endpoints, relative to placebo (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Gabapentin demonstrated noninferiority to placebo on standard deviation of lateral position and speed deviation but not for lane excursions. Diphenhydramine citrate demonstrated significant impairment relative to gabapentin and placebo on speed deviation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Other comparisons were either nonsignificant or statistically ineligible per planned, sequential comparisons. Secondary endpoints for sleepiness and cognitive performance were supportive of these conclusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Together, these data suggest that low\u2010dose gabapentin had no appreciable next\u2010day effects on simulated driving performance or cognitive functioning. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2530","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T05:02:44Z","timestamp":1459141364000},"page":"217-226","source":"Crossref","is-referenced-by-count":17,"title":["Next\u2010day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double\u2010blind, placebo\u2010controlled, crossover trial"],"prefix":"10.1002","volume":"31","author":[{"given":"Gary G.","family":"Kay","sequence":"first","affiliation":[{"name":"Cognitive Research Corporation  St. Petersburg Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard I.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Miami Research Associates  South Miami Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Wingertzahn","sequence":"additional","affiliation":[{"name":"Pfizer Consumer Healthcare  Madison New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamalie","family":"Jayawardena","sequence":"additional","affiliation":[{"name":"Pfizer Consumer Healthcare  Madison New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell P.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Neurotrials Research Inc.  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207459008994241"},{"issue":"2","key":"e_1_2_8_3_1","first-page":"S347","article-title":"Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey I","volume":"22","author":"Ancoli\u2010Israel S","year":"1999","journal-title":"Sleep"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.21.1831"},{"key":"e_1_2_8_5_1","unstructured":"BrownT DowB MarshallD AllenS:2007.Validation of stopping and turning behavior for novice drivers in the National Advanced Driving Simulator. Proceedings of the National Driving Simulation Conference Iowa City IA.http:\/\/www.nads\u2010sc.uiowa.edu\/bio_pub_pdf\/Brown_et_al_\u2010_Validation_of_stopping_and_turning_behavior.pdf(accessed 3 March 2015)."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2013.08.004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.4110"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.10.1573"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31816a9e4f"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2012.12.042"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2006.03.011"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2244"},{"key":"e_1_2_8_13_1","volume-title":"Proceedings of the 7th International Driving Symposium on Human Factors in Driver Assessment","author":"Kay GG","year":"2013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1001\/archinte.1997.00440410082009","article-title":"Initial and steady\u2010state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance","volume":"157","author":"Kay GG","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5664\/jcsm.2662","article-title":"Effects of armodafinil on simulated driving and self\u2010report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure","volume":"9","author":"Kay GG","year":"2013","journal-title":"J Clin Sleep Med"},{"key":"e_1_2_8_16_1","unstructured":"LeeJD WardN BoerE BrownTL BalkSA AhmadO:2013.Exploratory advanced research: Making driving simulators more useful for behavioral research \u2013 simulator characteristics comparison and model\u2010based transformation.http:\/\/www.nads\u2010sc.uiowa.edu\/publicationStorage\/20131399331159.N2013\u2010016_Making%20driving%20simul.pdf(accessed 5 January 2016)."},{"key":"e_1_2_8_17_1","first-page":"183","volume-title":"Alcohol, Drugs, and Traffic Safety","author":"Louwerens JW","year":"1987"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.5665\/SLEEP.1272"},{"key":"e_1_2_8_19_1","unstructured":"National SleepFoundation:2008.Sleep in America Poll.http:\/\/sleepfoundation.org\/sites\/default\/files\/2008%20POLL%20SOF.PDF(accessed 16 September 2014)."},{"key":"e_1_2_8_20_1","unstructured":"National Sleep Foundation:2009.Sleep in America Poll.http:\/\/sleepfoundation.org\/sites\/default\/files\/2009%20POLL%20HIGHLIGHTS.pdf(accessed 25 April 2014)."},{"key":"e_1_2_8_21_1","unstructured":"National Sleep Foundation:2015.Sleep in America Poll.http:\/\/sleepfoundation.org\/sleep\u2010polls\u2010data\/2015\u2010sleep\u2010and\u2010pain(accessed 12 September 2015)."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7643-9923-8_3"},{"key":"e_1_2_8_23_1","unstructured":"Pfizer Inc:2015.Neurontin\u00ae (gabapentin) capsule tablet oral solution . U.S. Prescribing Information.http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=630(accessed 21 October 2015)."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(00)00365-5"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02570506"},{"key":"e_1_2_8_26_1","volume-title":"A study comparing the hypnotic efficacies and residual effects on actual driving performance of midazolam 15\u2009mg, triazolam 0.5\u2009mg, temazepam 20\u2009mg and placebo in shiftworkers on night duty. Institute for Drugs","author":"Riedel WJ","year":"1988"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.4108"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2013.830211"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.21.1837"},{"key":"e_1_2_8_30_1","first-page":"525","article-title":"Validation of simulated assessment of teen driver speed management on rural roads","volume":"51","author":"Senserrick TM","year":"2007","journal-title":"Annu Proc Assoc Adv Automot Med"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615579314"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.182"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228029400300404"},{"key":"e_1_2_8_34_1","unstructured":"U.S. Food and Drug Administration:2010.Center for Drug Evaluation and Research. Application Number: 022399Orig1s000 Medical Review(s).http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022399Orig1s000MedR.pdf(accessed 29 September 2014)."},{"key":"e_1_2_8_35_1","unstructured":"U.S.FoodandDrugAdministration:2013.FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR.http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm352085.htm(accessed 16 September 2014)."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418050-00003"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1462-6"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S19639"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2011.652751"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-5-200003070-00004"},{"key":"e_1_2_8_41_1","volume-title":"Horizant\u00ae (gabapentin enacarbil) extended\u2010release tablets for oral use","author":"Inc XenoPort","year":"2013"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2530","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T03:01:38Z","timestamp":1696388498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/hup.2530"],"URL":"https:\/\/doi.org\/10.1002\/hup.2530","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}